Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002663 · ClinicalTrials.gov registry record · Phase 1
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
A Phase 1 study of EBV-induced Lymphomas and EBV-associated Malignancies, sponsored by Atara Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
- 1
- Study location
NCT00002663 is a Phase 1 study of EBV-induced Lymphomas and EBV-associated Malignancies that has completed, run by Atara Biotherapeutics. The registered enrollment target is 58 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00002663, a Phase 1 study of EBV-induced Lymphomas and EBV-associated Malignancies, has completed, sponsored by Atara Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.
Conditions Studied
Interventions
- BIOLOGICAL Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 1995-03 |
| Est. Completion | 2019-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002663
The ClinicalTrials.gov registry entry for NCT00002663 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atara Biotherapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with EBV-induced Lymphomas appearing as the primary indexed condition, and to 1 intervention - of which Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) is the first listed.
NCT00002663 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00002663 about?
NCT00002663 is a clinical study titled "Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies". The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.
What is the current status of trial NCT00002663?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 1995-03. Estimated completion is 2019-07.
What conditions does trial NCT00002663 study?
This clinical trial studies the following conditions: EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma.
What interventions are being tested in trial NCT00002663?
The interventions under investigation include: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002663?
This trial is sponsored by Atara Biotherapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002663 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.